| Canagliflozin and renal outcomes in type 2 diabetes and nephropathy V Perkovic, MJ Jardine, B Neal, S Bompoint, HJL Heerspink, ... New England journal of medicine 380 (24), 2295-2306, 2019 | 4950 | 2019 |
| Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes GL Bakris, R Agarwal, SD Anker, B Pitt, LM Ruilope, P Rossing, P Kolkhof, ... New England journal of medicine 383 (23), 2219-2229, 2020 | 1520 | 2020 |
| Cardiovascular events with finerenone in kidney disease and type 2 diabetes B Pitt, G Filippatos, R Agarwal, SD Anker, GL Bakris, P Rossing, A Joseph, ... New England Journal of Medicine 385 (24), 2252-2263, 2021 | 808 | 2021 |
| Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis R Agarwal, G Filippatos, B Pitt, SD Anker, P Rossing, A Joseph, P Kolkhof, ... European heart journal 43 (6), 474-484, 2022 | 433 | 2022 |
| Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes HC Gerstein, N Sattar, J Rosenstock, C Ramasundarahettige, R Pratley, ... New England journal of medicine 385 (10), 896-907, 2021 | 412 | 2021 |
| The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics MJ Jardine, KW Mahaffey, B Neal, R Agarwal, GL Bakris, BM Brenner, ... American journal of nephrology 46 (6), 462-472, 2018 | 240 | 2018 |
| Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes G Filippatos, SD Anker, R Agarwal, B Pitt, LM Ruilope, P Rossing, ... Circulation 143 (6), 540-552, 2021 | 227 | 2021 |
| Effect of alive probiotic on insulin resistance in type 2 diabetes patients: randomized clinical trial N Kobyliak, T Falalyeyeva, G Mykhalchyshyn, D Kyriienko, ... Diabetes & Metabolic Syndrome: Clinical Research & Reviews 12 (5), 617-624, 2018 | 177 | 2018 |
| Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial LM Ruilope, R Agarwal, SD Anker, GL Bakris, G Filippatos, C Nowack, ... American journal of nephrology 50 (5), 345-356, 2019 | 172 | 2019 |
| Design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial GL Bakris, R Agarwal, SD Anker, B Pitt, LM Ruilope, C Nowack, P Kolkhof, ... American Journal of Nephrology 50 (5), 333-344, 2019 | 151 | 2019 |
| Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial G Filippatos, SD Anker, R Agarwal, LM Ruilope, P Rossing, GL Bakris, ... Circulation 145 (6), 437-447, 2022 | 125 | 2022 |
| Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial R Agarwal, A Joseph, SD Anker, G Filippatos, P Rossing, LM Ruilope, ... Journal of the American Society of Nephrology 33 (1), 225-237, 2022 | 108 | 2022 |
| Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes G Filippatos, GL Bakris, B Pitt, R Agarwal, P Rossing, LM Ruilope, J Butler, ... Journal of the American College of Cardiology 78 (2), 142-152, 2021 | 98 | 2021 |
| Beneficial effects of probiotic combination with omega-3 fatty acids in NAFLD: a randomized clinical study N Kobyliak, L Abenavoli, T Falalyeyeva, G Mykhalchyshyn, L Boccuto, ... | 87 | 2018 |
| Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease Z Zhou, MJ Jardine, Q Li, BL Neuen, CP Cannon, D De Zeeuw, ... Stroke, 2021 | 72 | 2021 |
| Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium–glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis P Rossing, SD Anker, G Filippatos, B Pitt, LM Ruilope, AL Birkenfeld, ... Diabetes Care 45 (12), 2991-2998, 2022 | 67 | 2022 |
| Ендокринологія ПН Боднар, ЮІ Комісаренко, ГП Михальчишин, МІ Бобрик, ... Нова Книга, 2020 | 65 | 2020 |
| Vitamin D deficiency and immune disorders in combined endocrine pathology YI Komisarenko, MI Bobryk Frontiers in endocrinology 9, 387980, 2018 | 65 | 2018 |
| Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone R Agarwal, SD Anker, G Bakris, G Filippatos, B Pitt, P Rossing, L Ruilope, ... Nephrology Dialysis Transplantation 37 (6), 1014-1023, 2022 | 61 | 2022 |
| Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP‐1RA treatment: A subgroup analysis from the FIDELIO‐DKD trial P Rossing, R Agarwal, SD Anker, G Filippatos, B Pitt, LM Ruilope, A Amod, ... Diabetes, Obesity and Metabolism 24 (1), 125-134, 2022 | 47 | 2022 |
Назарій КобилякBogomolets National Medical University, department endocrinologyПідтверджена електронна адреса в nmu.kiev.ua
